Merck KGaA (XTRA:MRK) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

MRK Panoramica delle azioni

Merck KGaA opera come azienda scientifica e tecnologica in Germania.

MRK analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	1/6
Prestazioni passate	2/6
Salute finanziaria	6/6
Dividendi	4/6

Premi

Negoziato a 45.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 11.95% all'anno

Analisi del rischio

Non sono stati rilevati rischi per MRK dai nostri controlli di rischio.

Merck KGaA Concorrenti

Dermapharm Holding

XTRA:DMP

€1.9b

PharmaSGP Holding

XTRA:PSG

€254.2m

GSK

LSE:GSK

UK£62.7b

Chugai Pharmaceutical

TSE:4519

JP¥12.1t

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Merck KGaA
Prezzi storici delle azioni
Prezzo attuale dell'azione	€160.55
Massimo di 52 settimane	€177.00
Minimo di 52 settimane	€134.30
Beta	0.71
1Variazione di 1 mese	-8.70%
Variazione a 3 mesi	7.03%
Variazione di 1 anno	3.92%
3Variazione a 3 anni	-12.32%
Variazione a 5 anni	57.09%
Variazione dall'IPO	935.20%

Notizie e aggiornamenti recenti

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Sep 05

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Jul 24

Recent updates

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

Mar 26

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Mar 05

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Feb 14

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Dec 12

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Nov 09

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Aug 15

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

May 17

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Mar 29

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Jan 13

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

Oct 15

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Sep 19

MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Seems To Use Debt Quite Sensibly

Jul 11

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 21

Rendimenti per gli azionisti

	MRK	DE Pharmaceuticals	DE Mercato
7D	3.2%	3.1%	4.5%
1Y	3.9%	-12.1%	13.5%

Ritorno vs Industria: MRK ha superato il German Pharmaceuticals che ha restituito -13.5 % nell'ultimo anno.

Rendimento vs Mercato: MRK ha avuto una performance inferiore al mercato German che ha registrato un rendimento 6.7 % nell'ultimo anno.

Volatilità dei prezzi

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	3.1%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: MRK non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di MRK è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1668	62,176	Belen Garijo Lopez	www.merckgroup.com/en

Merck KGaA opera come società scientifica e tecnologica in Germania. Opera attraverso i segmenti Life Science, Healthcare ed Electronics. Il segmento Life Science dell'azienda offre strumenti, prodotti chimici e attrezzature per laboratori accademici, produttori biotecnologici e farmaceutici, nonché per il settore industriale.

Merck KGaA Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Merck KGaA con la sua capitalizzazione di mercato?
MRK statistiche fondamentali
Capitalizzazione di mercato	€69.80b
Guadagni(TTM)	€2.63b
Ricavi(TTM)	€20.87b

26.6x

Rapporto P/E

3.3x

Rapporto P/S

MRK è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MRK Conto economico (TTM)
Ricavi	€20.87b
Costo del fatturato	€8.68b
Profitto lordo	€12.19b
Altre spese	€9.57b
Guadagni	€2.63b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 14, 2024

Utile per azione (EPS)	6.04
Margine lordo	58.42%
Margine di profitto netto	12.58%
Rapporto debito/patrimonio netto	35.3%

Come si è comportato MRK nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.4%

Rendimento attuale del dividendo

36%

Rapporto di remunerazione

MRK Panoramica delle azioni

Premi

Analisi del rischio

Merck KGaA Concorrenti

XTRA:DMP

€1.9b

XTRA:PSG

€254.2m

LSE:GSK

UK£62.7b

TSE:4519

JP¥12.1t

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Recent updates

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Some Confidence Is Lacking In Merck KGaA's (ETR:MRK) P/E

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price

First quarter 2024 earnings: EPS exceeds analyst expectations

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20

Upcoming dividend of €2.20 per share

Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck KGaA (ETR:MRK) Has Affirmed Its Dividend Of €2.20

Dividend of €2.20 announced

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

There's Reason For Concern Over Merck KGaA's (ETR:MRK) Price

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 77% Above Its Share Price

Investor sentiment deteriorates as stock falls 15%

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Does Merck KGaA (ETR:MRK) Have A Healthy Balance Sheet?

Is There An Opportunity With Merck KGaA's (ETR:MRK) 49% Undervaluation?

Second quarter 2023 earnings: Revenues exceed analyst expectations

Merck KGaA, Annual General Meeting, Apr 26, 2024

Is Merck KGaA (ETR:MRK) A Risky Investment?

Are Investors Undervaluing Merck KGaA (ETR:MRK) By 36%?

First quarter 2023 earnings: Revenues in line with analyst expectations

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.3% yield

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Full year 2022 earnings: Revenues in line with analyst expectations

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Third quarter 2022 earnings: Revenues exceed analyst expectations

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of €1.85 per share

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2022 Results on Aug 04, 2022